Elscint develops first connectivity productIsraeli medical imaging vendor Elscint hopes to unveil its first home-grown medical image management product this year, according to sources at the Haifa company. Elscint is developing a mid-range
Israeli medical imaging vendor Elscint hopes to unveil its first home-grown medical image management product this year, according to sources at the Haifa company. Elscint is developing a mid-range connectivity product that would occupy a price point below that of Agfa's Impax PACS product, to which Elscint has worldwide marketing rights.
Elscint has been further behind most of its multimodality competitors in offering PACS and image management products. The company has been more active in the last two years, however, forming a connectivity group in 1995 and inking its marketing agreement with Agfa several months later.
The connectivity product under development is not a full-scale PACS network, but is a mid-tier offering designed for smaller hospitals, according to the source. It will include features for remote reading, image archiving, and other functions. Elscint hopes to debut the product some time this year.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.